EFFICACY AND SAFETY OF NIPOCALIMAB, AN FCRN BLOCKER, IN WARM AUTOIMMUNE HEMOLYTIC ANEMIA (WAIHA): ENERGY PHASE 2/3 STUDY DESIGN
a Albert Einstein College of Medicine/Montefiore Medical Center, Department of Hematology and Oncology, New York, United States
b Fondazione IRCCS Ca'Granda Ospedale Maggiore Plicilinico, Hematology Unit, Milan, Italy
c Janssen Global Services, LLC, Cambridge, United States
d Momenta Pharmaceuticals, Inc, Clinical Development Operations, Cambridge, United States
e Immunology Medical Affairs, Janssen Latin America, Bogotá, Colombia
Lido
1960
Vezesque se leu este artigo
737
Total PDF
1223
Total HTML
| Ano/Mês | Html | Total | |
|---|---|---|---|
| 2025 7 | 59 | 27 | 86 |
| 2025 6 | 65 | 21 | 86 |
| 2025 5 | 83 | 17 | 100 |
| 2025 4 | 65 | 21 | 86 |
| 2025 3 | 67 | 32 | 99 |
| 2025 2 | 42 | 28 | 70 |
| 2025 1 | 36 | 20 | 56 |
| 2024 12 | 39 | 19 | 58 |
| 2024 11 | 49 | 23 | 72 |
| 2024 10 | 43 | 18 | 61 |
| 2024 9 | 57 | 21 | 78 |
| 2024 8 | 62 | 31 | 93 |
| 2024 7 | 48 | 26 | 74 |
| 2024 6 | 56 | 29 | 85 |
| 2024 5 | 57 | 23 | 80 |
| 2024 4 | 31 | 25 | 56 |
| 2024 3 | 36 | 27 | 63 |
| 2024 2 | 24 | 26 | 50 |
| 2024 1 | 28 | 20 | 48 |
| 2023 12 | 35 | 26 | 61 |
| 2023 11 | 39 | 33 | 72 |
| 2023 10 | 19 | 33 | 52 |
| 2023 9 | 24 | 25 | 49 |
| 2023 8 | 16 | 14 | 30 |
| 2023 7 | 21 | 7 | 28 |
| 2023 6 | 17 | 23 | 40 |
| 2023 5 | 20 | 14 | 34 |
| 2023 4 | 14 | 15 | 29 |
| 2023 3 | 12 | 13 | 25 |
| 2023 2 | 11 | 17 | 28 |
| 2023 1 | 11 | 5 | 16 |
| 2022 12 | 23 | 27 | 50 |
| 2022 11 | 10 | 23 | 33 |
| 2022 10 | 4 | 8 | 12 |
Mostrar tudo
